“Of course there is scope to have that conversation,” Ms Chatwin said, “but our focus right now is on delivering the commitment we’ve made to the Australian government of 53 million doses.”
Ms Chatwin said AstraZeneca and CSL were on track to deliver the first vials by the end of March and produce one million doses per week.
“Then if we need to we’ll get to a discussion about further supply,” she said.
The issue will be crucial if the AstraZeneca vaccine needs to be altered to boost its efficacy against more infectious virus variants.
Early data from South Africa suggested the country’s dominant circulating variant significantly reduced its efficacy against mild disease.
But Australia’s Chief Medical Officer Professor Paul Kelly on Wednesday said the vaccine had shown no signs of being less effective at preventing severe illness.
“What we need to do is to get those vaccines out as soon as possible, either the AstraZeneca or the Pfizer vaccine, because they are both very strongly effective at saving lives, and that is the number-one perspective at the moment,” Professor Kelly said.
The federal government is expected to release further information about the AstraZeneca vaccine rollout after it was approved by the Therapeutic Goods Administration on Tuesday.
The states and territories have not yet been informed how many of the 53 million AstraZeneca doses they will receive, but the federal government has indicated their share will be proportionate to population size.
Ms Berejiklian said the government would have more to say about how the vaccine will be rolled out in the next week and everyone who wanted a vaccine will get one in due course.
The Premier said she would not be getting the vaccine early, despite her confidence in its efficacy.
“I would love to get mine early but I don’t think it’s fair. I think the people of the state would be upset if I jumped the queue, so I’ll wait my turn,” Ms Berejiklian said.
AstraZeneca has promised not to profit from its COVID-19 vaccine during the pandemic.
Asked what would trigger a decision to start charging countries more for the vaccine to turn a profit, Ms Chatwin said its future pricing structure was not a current consideration.
“There are still lots of countries reporting new cases – our primary focus right now is on delivering a safe and effective vaccine broadly and equitably throughout the pandemic and that is our primary focus at this time,” she said.
“We’re on the cusp of a rollout, we’re trying to do what we can as a company to make an impact on this huge global health crisis and that’s what we’re focused on right now.”
NSW Chief Health Officer Dr Kerry Chant said she expected the population would come forward to receive their vaccines en masse.
“We’ve been in a good position that we’ve been able to wait [for] the international experience with the vaccine and learn from that,” Dr Chant said.
NSW’s quarantine workers – including nurses, doctors, police officers, security guards and cleaners – will be the first to roll up their sleeves for the Pfizer vaccine from Monday. They will be followed by frontline healthcare workers at testing clinics, emergency departments, COVID-19 wards, intensive care units and ambulance services.
NSW recorded no new locally acquired cases from 23,463 tests in the latest 24-hour reporting period. It’s the 31st consecutive day of no community cases.
Emma reports on healthcare companies for The Age and Sydney Morning Herald. She is based in Melbourne.
Kate Aubusson is Health Editor of The Sydney Morning Herald.